Let&#x27;s say we stopped exclusive licensing for government funded research. Then, when commercialized, drugs would be available from multiple competing sources. Or the IP could be set free, for generics manufacturers to pick up.<p>Maximizing rent-seeking doesn&#x27;t seem like the wisest course of action.